Follicular Lymphoma  >>  Xcytrin (motexafin gadolinum)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xcytrin (motexafin gadolinum) / AbbVie
NCT00086034: Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma

Completed
2
35
US
Motexafin gadolinium
Pharmacyclics LLC.
Lymphoma, Non-Hodgkin's Lymphoma
 
 
NCT01549886: Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

Terminated
2
5
US
Y-90-Zevalin, [90Y]- ibritumomab tiuxetan (Zevalin), Moxtezafin Gadolinium, MGD, Rituximab
Spectrum Pharmaceuticals, Inc
Non-Hodgkin's Lymphoma
06/14
05/15
NCT00089284: Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

Terminated
1/2
30
US
Rituxan, rituximab IDEC-C2B8, motexafin gadolinium, MGd, Xcytrin® (motexafin gadolinium) Injection,, NSC 695238, 111Indium-Zevalin and 90Yttrium-Zevalin, Ibritumomab-tiuxetan
Northwestern University, Robert H. Lurie Cancer Center
Non-Hodgkin's Lymphoma (NHL)
01/07
08/08

Download Options